Literature DB >> 8529109

Cell type-dependent modulation of the dominant negative action of human mutant thyroid hormone beta 1 receptors.

R Wong1, X G Zhu, M A Pineda, S Y Cheng, B D Weintraub.   

Abstract

BACKGROUND: Mutations in the ligand-binding domain of the thyroid hormone receptor beta (TR beta) gene cause the syndrome of resistance to thyroid hormone (RTH). The clinical phenotype results from the antagonism of the normal TR alpha and the non-mutated TR beta alleles by the TR beta 1 mutants, via a dominant negative effect. There is, however, marked heterogeneity of organ resistance within and among kindreds with RTH. This study examines the potential role of cell type in modulating the dominant negative potency of human TR beta 1 (h-TR beta 1) mutants.
MATERIALS AND METHODS: Transient transfections were performed in HeLa and NIH3T3 cells, using a wild type (WT) and three naturally occurring mutant h-TR beta 1 constructs, and three natural thyroid hormone response elements (TREs). Immunocytochemistry was performed to detect levels of TR beta 1 expression in these two cell types. In order to determine how TR beta 1 interacts with other cellular partners, gel-shift analyses using HeLa and NIH3T3 nuclear extracts were performed.
RESULTS: Transfection studies using WT h-TR beta 1 in HeLa and NIH3T3 cells, showed that the 3,3',5-triiodothyronine (T3)-induced transactivation of the different TREs varied between cell types. Unlike the non-T3-binding h-TR beta 1 mutant, PV, mutants ED and OK displayed the expected T3-induced dose responsiveness in these two cell types. For each TRE examined, the magnitude of the dominant negative effect varied between the cell types. The levels of receptor expression in HeLa and NIH3T3 cells were identical, as determined by immunocytochemistry. Gel-shift analyses showed differences in the formation of hetero- and homodimers depending on both the cell type and TRE motif.
CONCLUSIONS: The cell type in which a mutant receptor operates affects the relative amounts of hetero- and homodimers. Together with the nature of the mutation and the TRE-motif, this could modulate the dominant negative action of mutant receptors in different tissues, which, in turn, could contribute to the variable phenotypic characteristics of RTH.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8529109      PMCID: PMC2229906     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  39 in total

1.  Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone.

Authors:  S Refetoff; L T DeWind; L J DeGroot
Journal:  J Clin Endocrinol Metab       Date:  1967-02       Impact factor: 5.958

2.  Characterization and tissue expression of multiple triiodothyronine receptor-auxiliary proteins and their relationship to the retinoid X-receptors.

Authors:  A Sugawara; P M Yen; D S Darling; W W Chin
Journal:  Endocrinology       Date:  1993-09       Impact factor: 4.736

3.  Differential expression of mutant and normal beta T3 receptor alleles in kindreds with generalized resistance to thyroid hormone.

Authors:  A J Mixson; P Hauser; G Tennyson; J C Renault; D L Bodenner; B D Weintraub
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

4.  Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance.

Authors:  T Nagaya; J L Jameson
Journal:  J Biol Chem       Date:  1993-07-25       Impact factor: 5.157

5.  cis-acting elements of the rat growth hormone gene which mediate basal and regulated expression by thyroid hormone.

Authors:  F Flug; R P Copp; J Casanova; Z D Horowitz; L Janocko; M Plotnick; H H Samuels
Journal:  J Biol Chem       Date:  1987-05-05       Impact factor: 5.157

6.  The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation.

Authors:  M Au-Fliegner; E Helmer; J Casanova; B M Raaka; H H Samuels
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

7.  In vitro transcriptional studies of the roles of the thyroid hormone (T3) response elements and minimal promoters in T3-stimulated gene transcription.

Authors:  C S Suen; P M Yen; W W Chin
Journal:  J Biol Chem       Date:  1994-01-14       Impact factor: 5.157

8.  Dominant negative inhibition by mutant thyroid hormone receptors is thyroid hormone response element and receptor isoform specific.

Authors:  A M Zavacki; J W Harney; G A Brent; P R Larsen
Journal:  Mol Endocrinol       Date:  1993-10

9.  Divergent dimerization properties of mutant beta 1 thyroid hormone receptors are associated with different dominant negative activities.

Authors:  E Hao; J B Menke; A M Smith; C Jones; M E Geffner; J M Hershman; J P Wuerth; H H Samuels; D K Ways; S J Usala
Journal:  Mol Endocrinol       Date:  1994-07

10.  Identical mutations in unrelated families with generalized resistance to thyroid hormone occur in cytosine-guanine-rich areas of the thyroid hormone receptor beta gene. Analysis of 15 families.

Authors:  R E Weiss; M Weinberg; S Refetoff
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

View more
  3 in total

1.  Brain glucose utilization in mice with a targeted mutation in the thyroid hormone alpha or beta receptor gene.

Authors:  Y Itoh; T Esaki; M Kaneshige; H Suzuki; M Cook; L Sokoloff; S Y Cheng; J Nunez
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

2.  Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors.

Authors:  S M Yoh; V K Chatterjee; M L Privalsky
Journal:  Mol Endocrinol       Date:  1997-04

3.  Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53.

Authors:  N Yap; C L Yu; S Y Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.